Dansyl Ethylenediamine

Dansyl Ethylenediamine

SCHEMBL1293231

CN(C)c1cccc2c(S(=O)(=O)NCCN)cccc12

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.63
CYP1A2 P05177 3/20 0.63
CYP2C19 P33261 3/20 0.63
CYP2D6 P10635 2/20 0.63
CYP2C9 P11712 2/20 0.63
KDM4E B2RXH2 2/20 0.63
HSD17B10 Q99714 2/20 0.63
FPR2 P25090 1/20 0.63
MTOR P42345 1/20 0.63
CSNK1A1 P48729 1/20 0.63
MYLK Q15746 1/20 0.63
TP53 P04637 2/20 0.62
NFKB1 P19838 2/20 0.62
THPO P40225 2/20 0.62
APEX1 P27695 1/20 0.62
BLM P54132 1/20 0.62
PMP22 Q01453 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
HDAC4 P56524 1/20 0.61
HDAC10 Q969S8 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dansyl Ethylenediamine SCHEMBL30497055 1.00 CYP3A4 (0.63) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL8488157 0.92 HDAC4 (0.65) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL5384708 0.91 HDAC4 (0.67) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL17312330 0.89 HDAC4 (0.69) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL29729303 0.89 HDAC4 (0.69) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL6361662 0.89 HDAC4 (0.69) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL107807 0.89 HDAC4 (0.69) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL107806 0.89 HDAC4 (0.69) CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL2639212 0.89 HDAC4 (0.61) CYP1A2CYP2C19KDM4EHSD17B10HDAC4
SCHEMBL4126957 0.88 HDAC4 (0.71) HDAC4HDAC10HDAC6HDAC5EDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023137518-A1 PLATINUM COMPLEXES Western Sydney University (AU) 2023-07-27 WO claimed
US-10768111-B2 Fluorescent supramolecular biosensor and preparation method thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2020-09-08 US claimed
WO-2015033743-A1 METHOD FOR PREPARING LABELED SUGAR CHAIN SAMPLE 住友ベークライト株式会社 (JP) 2015-03-12 WO claimed
US-20110089033-A1 METHOD OF PREPARING SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD OF ANALYZING SUGAR CHAIN SUMITOMO BAKELITE CO., LTD. (JP) 2011-04-21 US claimed
EP-2295962-A1 METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN Sumitomo Bakelite Co., Ltd. (JP) 2011-03-16 EP claimed
WO-2009150834-A1 METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN 住友ベークライト株式会社 (JP) 2009-12-17 WO claimed
US-7605146-B2 Process for producing an amide compound NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) 2009-10-20 US claimed
US-20020077456-A1 Process for producing an amide compound NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) 2002-06-20 US claimed
EP-1199312-A2 Process for producing an amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-04-24 EP claimed
JP-2003448-A None JP disclosed
JP-8105888-A None JP disclosed
EP-4724110-A1 PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY WUXI XDC SINGAPORE PRIVATE LIMITED (SG) 2026-04-15 EP disclosed
US-12545747-B2 Method, kit, and device for preparing glycan from glycoprotein NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2026-02-10 US disclosed
EP-4646595-A1 PEPTIDE SEQUENCER Oregon Health & Science University (US) 2025-11-12 EP disclosed
US-5196576-A Medical imaging of liver tissue NIHON MEDI-PHYSICS CO., LTD. (JP) 1993-03-23 US disclosed
US-5138039-A Diagnosis, therapy NIHON MEDI-PHYSICS CO., LTD (JP) 1992-08-11 US disclosed
EP-0365627-A4 CATALYTIC HYBRIDIZATION SYSTEMS FOR THE DETECTION OF NUCLEIC ACID SEQUENCES BASED ON THEIR ACTIVITY AS COFACTORS IN CATALYTIC REACTIONS IN WHICH A COMPLEMENTARY LABELED NUCLEIC ACID PROBE IS CLEAVED 1990-10-10 EP disclosed
EP-0365627-A1 CATALYTIC HYBRIDIZATION SYSTEMS FOR THE DETECTION OF NUCLEIC ACID SEQUENCES BASED ON THEIR ACTIVITY AS COFACTORS IN CATALYTIC REACTIONS IN WHICH A COMPLEMENTARY LABELED NUCLEIC ACID PROBE IS CLEAVED. UNIV IOWA RES FOUND (US) 1990-05-02 EP disclosed
JP-H023448-A FLUORESCENT ACRYLAMIDE COMPOUND SEIKO INSTR INC 1990-01-09 JP disclosed
WO-1989009284-A1 CATALYTIC HYBRIDIZATION SYSTEMS FOR THE DETECTION OF NUCLEIC ACID SEQUENCES BASED ON THEIR ACTIVITY AS COFACTORS IN CATALYTIC REACTIONS IN WHICH A COMPLEMENTARY LABELED NUCLEIC ACID PROBE IS CLEAVED UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1989-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077456-A1 Process for producing an amide compound NAAA, ACMSD, CPS1 CYP3A4 892/4885CYP1A2 1673/4885CYP2C19 1792/4885
US-10768111-B2 Fluorescent supramolecular biosensor and preparation method thereof NOD2, CACYBP, CALCOCO2 CYP3A4 4530/4885CYP1A2 4841/4885CYP2C19 4546/4885
US-12545747-B2 Method, kit, and device for preparing glycan from glycoprotein FUT7, FUT4, SIGLEC7 CYP3A4 2860/4885CYP1A2 4270/4885CYP2C19 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.